NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion
Medesis Pharma is developing a radioprotection drug to treat people irradiated following
TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing
Text currently
Alzheimer’s disease is the most frequent cause of dementia and one of the most
The objective of the radioprotection program is to develop a radiomitigation drug,
AONYS® is a mix of lipidic components that spontaneously assemble into a water-in-oil
NanoLithium® (NP03) is a disease-modifying nano dose formulation of lithium citrate
Directly linked to 137Cs are numerous diseases not only limited to the increased
Medesis is a clinical development stage biopharmaceutical company that is engaged
